The effect of DAAs therapy for patients with HCV infection on prognosis and incidence of HCC

The effect of DAAs therapy for patients with HCV infection on prognosis and incidence of HCC - Effect of DAAs on incidence of HCC and prognosis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031091

Enrollment

400

Registered

2018-01-31

Start date

2016-05-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with HCV infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HCV infected patients who were treated and achieved SVR between 2011 and 2026

Exclusion criteria

Exclusion criteria: 1) Patients with difficult-to-control heart disease 2) Other patients judged to be inappropriate to participate in the study by the primary physician

Design outcomes

Primary

Measure	Time frame
To investigate incidence of HCC and prognosis after HCV eradication. To analyze risk factor of those	—

Secondary

Measure	Time frame
1 HCC incidence and prognosis in HD patients with HCV infection. To compare HCC incidence and prognosis between patient with or without IFN-therapy 2 To investigate change in ALT and AFP 3 To investigate the change in liver fibrosis and steatosis after SVR 4 To investigate the change in lipid/glucose/Fe metabolismafter SVR 5 To investigate the rate of Hospitalization due to liver disease	—

Countries

Japan

Contacts

Public ContactGoki Suda

Graduate School of Medicine, Hokkaido University Department of Gastroenterology and Hepatology

gsudgast@pop.med.hokudai.ac.jp011-716-2111

Outcome results